Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31587365 | 0.98 | KDM4E (0.55) | KDM4EHSD17B10LMNAAXLALDH1A1 | |
| SCHEMBL11816973 | 0.89 | KDM4E (0.48) | KDM4EHSD17B10LMNAAXLALDH1A1 | |
| SCHEMBL4323448 | 0.86 | NPC1 (0.49) | KDM4EHSD17B10LMNAAXLALDH1A1 | |
| SCHEMBL29439014 | 0.85 | KDM4E (0.61) | KDM4EHSD17B10LMNAALDH1A1MEN1 | |
| SCHEMBL4371528 | 0.85 | KDM4E (0.61) | KDM4EHSD17B10LMNAALDH1A1MEN1 | |
| SCHEMBL1170729 | 0.83 | ALDH1A1 (0.57) | KDM4EHSD17B10LMNAAXLALDH1A1 | |
| SCHEMBL31578181 | 0.81 | ALDH1A1 (0.50) | KDM4EHSD17B10LMNAAXLALDH1A1 | |
| SCHEMBL12930776 | 0.81 | ALDH1A1 (0.50) | KDM4EHSD17B10LMNAALDH1A1MEN1 | |
| SCHEMBL10146397 | 0.81 | HSD17B10 (0.50) | KDM4EHSD17B10LMNAALDH1A1MEN1 | |
| SCHEMBL9304566 | 0.80 | ALDH1A1 (0.48) | KDM4EHSD17B10LMNAAXLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034105-A1 | Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors | THE FIRST AFFILIATED HOSPITAL OF XI'AN JIAOTONG UNIVERSITY (CN) | 2026-02-05 | — | — | US | disclosed |
| US-11851446-B2 | Probes for imaging Huntingtin protein | CHDI FOUNDATION, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3752498-B1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | UNIV CALIFORNIA (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4125861-A2 | PROTEIN-PROTEIN INTERACTION STABILIZERS | The Regents of the University of California (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | NEW YORK UNIVERSITY (US) | 2022-07-26 | — | — | US | disclosed |
| EP-3197277-B1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210380608-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2021-12-09 | — | — | US | disclosed |
| WO-2021203016-A2 | PROTEIN-PROTEIN INTERACTION STABILIZERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| WO-1997020798-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1997-06-12 | — | — | WO | disclosed |
| US-4074046-A | REACTING NITROGENEOUS COMPOUND WITH CARBON MONOXIDE | AMERICAN CYANAMID COMPANY (US) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851446-B2 | Probes for imaging Huntingtin protein | HTT, HYPK, HSPBP1 | KDM4E 4585/4885HSD17B10 966/4885LMNA 2021/4885 |
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | CAMKK2, CAMKK1, CAMK1 | KDM4E 2731/4885HSD17B10 2670/4885LMNA 1984/4885 |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | KDM4E 2132/4885HSD17B10 1746/4885LMNA 225/4885 |
| US-20260034105-A1 | Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors | PIK3R1, PIK3R4, PIK3R2 | KDM4E 3651/4885HSD17B10 946/4885LMNA 4236/4885 |
| US-20210380608-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | KDM4E 4585/4885HSD17B10 966/4885LMNA 2021/4885 |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | HSPBP1, HSPA8, HSPH1 | KDM4E 3796/4885HSD17B10 2477/4885LMNA 2827/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | KDM4E 1506/4885HSD17B10 2347/4885LMNA 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.